Atossa Therapeutics, Inc. ATOS 深 沪
已收盘 02-06 16:00:00 美东时间
5.34
+0.010
+0.19%
华盛通- 最 高5.54
- 今 开5.33
- 成交量 15.61万股
- 最 低 5.21
- 昨 收 5.33
- 总市值 4598.50万
- 52周最高 19.35
- 市盈率 静 --
- 换手率 1.81%
- 52周最低 4.905
- 委 比 -82.67%
- 总股本 861.14万
- 历史最高 33480.00
- 量 比 0.17
- 振 幅 6.19%
- 历史最低 5.21
- 每 手 1
- 风险率 1.79%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Atossa Therapeutics Passes Five-Year Reauthorization Of Rare Pediatric Disease Priority Review Voucher Program
Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of high unmet clinical need, today reaffirmed its
02-05 21:41
Atossa Therapeutics Announces 15-for-1 Reverse Stock Split
Atossa Therapeutics Announces 15-for-1 Reverse Stock Split Atossa Therapeutics Inc. has announced a 15-for-1 reverse stock split of its common stock, effective at 12:01 a.m. Eastern Time on February 2, 2026. The company's shares will begin trading on a split-adjusted basis under a new CUSIP number,
01-26 21:02
Atossa Therapeutics shares are trading higher after the company's (Z)-endoxifen received FDA Orphan Drug Designation for Duchenne muscular dystrophy.
Atossa Therapeutics shares are trading higher after the company's (Z)-endoxifen...
01-17 05:43
Atossa Therapeutics' (Z)-Endoxifen Receives FDA Orphan Drug Designation For Duchenne Muscular Dystrophy
Designation further supports (Z)-Endoxifen program into rare pediatric neuromuscular disease along with previously received Rare Pediatric Disease DesignationSEATTLE, Jan. 16, 2026 /PRNewswire/ -- Atossa Therapeutics,
01-17 05:41
Atossa Therapeutics outlines strategy for lead (Z)-Endoxifen program
The latest announcement is out from Atossa Therapeutics ( ($ATOS) ). In a recen...
01-09 21:49
Atossa Therapeutics shares are trading higher the company received an FDA study may proceed letter for the investigational new drug application for (Z)-endoxifen in metastatic breast cancer.
Atossa Therapeutics shares are trading higher the company received an FDA study...
01-06 21:17
Atossa Therapeutics Announces FDA Issues 'Study May Proceed' Letter For Company's Trial In Metastatic Breast Cancer
Atossa Therapeutics, Inc. (NASDAQ:ATOS), a clinical-stage biopharmaceutical company developing innovative medicines for unmet medical needs, today announced that the U.S. Food and Drug Administration ("FDA") issued a
01-06 21:16
Atossa Therapeutics Presents Four Clinical Trial Updates On (Z)-Endoxifen At SABCS
Studies highlight findings regarding the potential use of (Z)-endoxifen to advance breast cancer treatment and risk reductionSEATTLE, Dec. 15, 2025 /PRNewswire/ -- Atossa Therapeutics, Inc. (NASDAQ:ATOS) ("Atossa" or the
2025-12-15 21:03
Why Are Shares Of Atossa Therapeutics Up Today?
Atossa Therapeutics, Inc. (NASDAQ: ATOS) stock is trading higher on Thursday. Here's what investors need to know.
2025-12-12 01:26
Atossa Therapeutics Secures U.S. Patent for Methods of Making And Using Endoxifen
New patent further strengthens global intellectual property estate supporting Atossa's lead program across the breast cancer spectrum and other hormone-driven conditionsSEATTLE, Dec. 9, 2025 /PRNewswire/ -- Atossa
2025-12-09 21:06
